文献速递甲状腺疾病垂体与肾上腺疾病

OATP1C1 突变致严重脑低代谢与青少年神经退行性变

Mutated Thyroid Hormone Transporter OATP1C1 Associates with Severe Brain Hypometabolism and Juvenile Neurodegeneration.
PubMed 文献 · Thyroid · 2018-01-01

本文首次报告一例 OATP1C1 功能缺失患者:15.5 岁女孩,第一年发育正常后逐渐出现痴呆、痉挛和畏寒,脑影像示灰白质变性和严重葡萄糖低代谢。外显子测序发现 OATP1C1 纯合错义突变 D252N,体外实验示突变蛋白膜定位受损、细胞甲状腺素摄取减少;Triac 治疗后部分临床改善。

要点

  • OATP1C1 缺陷可致脑特异性甲状腺功能减退和神经退行性变。
  • D252N 突变损害 OATP1C1 质膜定位并降低细胞甲状腺素摄取。
  • Triac 治疗在多个临床维度改善该患者病情。

核心结论

  • OATP1C1 功能缺失是首例报告的人类脑特异性甲状腺功能减退和神经退行性变病因。

研究设计与样本

  • 病例报告:15.5 岁女孩,行患者及父母外显子测序,并行体外摄取、免疫印迹和免疫细胞化学实验。

主要发现

  • 患者第一年发育正常,后逐渐出现痴呆、痉挛和畏寒,脑影像示灰白质变性和严重葡萄糖低代谢。
  • 外显子测序发现 OATP1C1 纯合错义突变 D252N。
  • 体外实验示突变 OATP1C1 质膜定位受损、细胞甲状腺素摄取减少。
  • Triac 治疗后患者临床状况在多个维度改善。

关键数值与推荐

  • OATP1C1 突变 D252N 为纯合错义突变,高度保守的天冬氨酸 252 变为天冬酰胺。

临床怎么用

  • 对不明原因青少年神经退行性变伴脑低代谢者,可考虑 OATP1C1 缺陷并行基因检测。
  • Triac 可能改善 OATP1C1 缺陷患者的临床状况。

局限性

  • 仅报告一例患者,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Thyroid hormones (TH) are essential for brain development and function. The TH transporters monocarboxylate transporter 8 (MCT8) and organic anion transporter1 C1 (OATP1C1) facilitate the transport of TH across the blood-brain barrier and into glia and neuronal cells in the brain. Loss of MCT8 function causes Allan-Herndon-Dudley syndrome (AHDS, OMIM 300523) characterized by severe intellectual and motor disability due to cerebral hypothyroidism. Here, the first patient with loss of OATP1C1 function is described. The patient is a 15.5-year-old girl with normal development in the first year of life, who gradually developed dementia with spasticity and intolerance to cold. Brain imaging demonstrated gray and white matter degeneration and severe glucose hypometabolism. METHODS: Exome sequencing of the patient and parents was performed to identify the disease-causing mutation, and the effect of the mutation was studied through a panel of in vitro experiments, including thyroxine uptake studies, immunoblotting, and immunocytochemistry. Furthermore, the clinical effects of treatment with the triiodothyronine analogue triiodothyroacetic acid (Triac) are described. RESULTS: Exome sequencing identified a homozygous missense mutation in OATP1C1, changing the highly conserved aspartic acid 252 to asparagine (D252N). In vitro, the mutated OATP1C1 displays impaired plasma membrane localization and decreased cellular thyroxine uptake. After treatment with Triac, the clinical condition improved in several domains. CONCLUSIONS: This is the first report of human OATP1C1 deficiency compatible with brain-specific hypothyroidism and neurodegeneration.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Strømme P, Groeneweg S, Lima de Souza EC, et al. Mutated Thyroid Hormone Transporter OATP1C1 Associates with Severe Brain Hypometabolism and Juvenile Neurodegeneration. Thyroid. 2018. PMID: 30296914. doi:10.1089/thy.2018.0595

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。